Bullied in Norway, Merck Sees Sales of Blockbuster Dive
This article is for subscribers only.
There’s a price war brewing for some very lucrative drugs in Europe, and it started in peaceful Norway.
The first salvo was fired in February when Orion Oyj cut the local price for a copycat version of Merck & Co.’s blockbuster arthritis medicine Remicade by 69 percent of the original drug’s cost. The move paid off swiftly: by March, Orion’s version of the injection had grabbed half the market.